登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《WHO，12月17日，WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries》

  • 来源专题：COVID-19科研动态监测
  • 编译者： YUTING
  • 发布时间：2021-12-24

  • Today, the World Health Organization issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus. The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.

    WHO’s EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

    “Even with new variants emerging, vaccines remain one of the most effective tools to protect people against serious illness and death from SARS-COV-2,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products. ‘This listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10% of their populations, while 98 countries have not reached 40%.”

    CovovaxTM was assessed under the WHO EUL procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India. The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally.

    CovovaxTM is a subunit of the vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses and is stable at 2 to 8 °C refrigerated temperatures. The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.

    The originator product produced by Novavax, named NuvaxovidTM, is currently under assessment by the European Medicines Agency (EMA). WHO will complete its own assessment of this vaccine once the EMA has issued its recommendation.

  • 原文来源：https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries
11浏览量
原文链接
相关报告

  • 《Nature，2月5日，Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-25
    • Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA Sahil Loomba, Alexandre de Figueiredo, Simon J. Piatek, Kristen de Graaf & Heidi J. Larson Nature Human Behaviour (2021) Abstract Widespread acceptance of a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be the next major step in fighting the coronavirus disease 2019 (COVID-19) pandemic, but achieving high uptake will be a challenge and may be impeded by online misinformation. To inform successful vaccination campaigns, we conducted a randomized controlled trial in the UK and the USA to quantify how exposure to online misinformation around COVID-19 vaccines affects intent to vaccinate to protect oneself or others. Here we show that in both countries—as of September 2020—fewer people would ‘definitely’ take a vaccine than is likely required for herd immunity, and that, relative to factual information, recent misinformation induced a decline in intent of 6.2 percentage points (95th percentile interval 3.9 to 8.5) in the UK and 6.4 percentage points (95th percentile interval 4.0 to 8.8) in the USA among those who stated that they would definitely accept a vaccine. We also find that some sociodemographic groups are differentially impacted by exposure to misinformation. Finally, we show that scientific-sounding misinformation is more strongly associated with declines in vaccination intent.
    48浏览量
    原文链接

  • 《CIDRAP，2月15日，Study suggests maternal COVID-19 vaccination protects babies》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-23
    • COVID-19 vaccination during pregnancy—already known to protect women from hospitalization and severe complications—can also protect babies younger than 6 months, researchers reported today. In other COVID-19 research developments, a separate team that looked at COVID-19 hospitalizations in kids found that levels jumped dramatically during the Omicron variant surge, especially in kids younger than 4, a group not eligible yet for vaccination. Real-world evidence of baby benefits The study on the impact of COVID-19 vaccination during pregnancy on the youngest infants examined hospitalization trends across 20 children's hospitals in 17 states from July 2021 through January 2022. The team published its findings today in an early online edition of Morbidity and Mortality Weekly Report (MMWR). At a Centers for Disease Control and Prevention (CDC) briefing today, Dana Meaney-Delman, MD, MPH, who wasn't involved in the study and heads the CDC's Infant Outcomes Monitoring Research and Prevention Branch, said scientists already now that SARS-CoV-2 antibodies are found in umbilical cord blood and can cross the placenta. However, she said it wasn't known if the maternal antibodies provided any protection to babies. "Now we have real-world evidence in babies younger than 6 months," she said. The study authors found that babies born to pregnant women who had received two doses of an mRNA vaccine were 61% less likely than those born to unvaccinated moms to be hospitalized with a COVID-19 infection. Of 176 babies hospitalized with COVID-19 over the study period, 84% were born to mothers who were unvaccinated during pregnancy. Of 43 infants who were admitted to the intensive care unit, 88% had mothers who were unvaccinated. Of the critically ill babies, one died—a child of an unvaccinated mother. Effectiveness was lower if a woman was vaccinated in early pregnancy, during the first 20 weeks, with protection at 32% versus 80% in later pregnancy. But researchers warn that the confidence interval is wide and that the pattern should be interpreted with caution. Senior author Manish Patel, MD, with the CDC's COVID-19 Emergency Response Team, said the numbers were too small to look at the impact of vaccination by trimester. And Delman said there aren't any changes in recommendations that relate to the timing of COVID-19 vaccination during pregnancy. She said vaccination levels in pregnant women are increasing and are encouraging, but aren't where health experts need them to be. Maternal vaccination has been found to help young infants against other infections such as flu and pertussis, and now extend to COVID-19. "This new study will undoubtedly be factoring into my counseling sessions," Meaney-Delman said. Omicron hits youngest kids hardest In a snapshot of COVID-19 hospitalizations in children and adolescents, another research team examined data from 14 states covering July 2021 to January 2022, a time that covered Delta circulation, then quickly transitioned to Omicron in December. Their findings also appear in an early online edition of MMWR. Once the Omicron variant became dominant, hospitalizations in children and adolescents reached levels that were four time higher than those of Delta's peak. The largest increase in hospitalizations was in children ages 0 to 4, who weren't eligible for vaccination. During the study period, adolescents ages 12 to 17 were the only pediatric group approved for COVID-19 vaccination during the entire study period. When researchers compared their hospitalizations to that of unvaccinated peers, they found that levels were six times higher in the unvaccinated group. "All persons who are eligible for vaccination should receive and stay up to date with COVID-19 vaccines to reduce the risk for severe disease for themselves and others with whom they come into contact, including children who are currently too young to be vaccinated," the group wrote.
    92浏览量
    原文链接